Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sonnet BioTherapeutics Holdings, Inc. - Common Stock (NQ:SONN)

3.920 -0.230 (-5.54%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sonnet BioTherapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting
Via ACCESSWIRE
InvestorNewsBreaks – Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) Releases Pricing of Underwritten Public Offering to Total Estimated $15M
Via Investor Brand Network
Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010
Via ACCESSWIRE
Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
Via ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022
Via ACCESSWIRE
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
Via ACCESSWIRE
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010
Via ACCESSWIRE
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
Via ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
- Represents Sonnet's first IND cleared - Phase 1 trial initiation expected in 2Q22 PRINCETON, NJ / ACCESSWIRE / March 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
PRINCETON, NJ / ACCESSWIRE / February 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
- SON-1010 and SON-080 on track to initiate clinical studies during the second quarter of 2022 - Completed R&D manufacturing for SON-1210 non-GLP toxicity study in non-human primates, with study... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
- SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 and 12, was selected based on data generated in a mouse melanoma study comparing three bispecific constructs - Selection of the... 
From Sonnet BioTherapeutics, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.